Hence, since pediatric SPTCL increases the likelihood of harboring HAVCR2 mutations, the use of IST-based regimens in this setting of patients would be an appropriate therapeutic approach instead of aggressive CMT-based regimens. This evidence concerns the gene HAVCR2 and subcutaneous panniculitis-like T-cell lymphoma.